TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07405190: Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

Sponsor: Massachusetts General Hospital · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 46 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$11,827,200

Rescue Site Savings

+$7,807,800

Unlock Full NCT07405190 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07405190 Rescue Dossier →